Dr. Habeebbullal Life Sciences Ltd (BSE: 539267) is a Hyderabad, Telangana-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹26 Cr, it ranks #4,249 by market cap among the 6,197 Indian listed companies on FinBizNet, and #9 of 10 in Life Sciences Tools and Services. At ₹12.40 (as of 19 Nov 2026), the share price is 49.5% below its 52-week high of ₹24.55 and 22.2% above its 52-week low of ₹10.15. The share price is down 45.3% over one year and up 6.2% over three months.
| Current Price | ₹12.40 |
|---|---|
| Market Cap | ₹26 Cr |
| BSE Code | 539267 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -68.79% |
| Return on Assets | -36.38% |
| 52-Week Range | ₹10.15 – ₹24.55 |
| 1-Year Price Change | -45.3% |
| 3-Month Price Change | +6.2% |
| Beta (1Y) | -0.57 |
| Headquarters | Hyderabad, Telangana |
| Website | drhlsl.com |
Delivery averaged 84.7% of traded volume across 16 BSE sessions (26 Oct 2026 – 19 Nov 2026).
Samsrita Labs Limited operates as a biopharmaceutical company in India. The company offers DNA, RNA, and chromosomal-based tests for oncology, pharmacogenomics, infectious diseases, genetic disorders, transplantation typing, and prenatal and pre-implantation genetic diagnostics; and quantitative/real-time polymerase chain reaction (qPCR), multiplex ligation-dependent probe amplification (MLPA), Sanger and Next Generation Sequencing (NGS), karyotype, and fluorescence in-situ hybridization analysis. It is also involved in the stem cell research and therapy, including regenerative medicine, bio-artificial organ scaffold development, nanobiotechnology, nano formulation of cancer drugs, molecular genetics, and molecular virology for the body organs of the liver, pancreas, neural, cardiac, vascular, renal, and orthopedic systems. In addition, company engages in new drug discovery, targeting therapeutic areas, such as Wilson's disease, non-alcoholic steatohepatitis, neuropathic pain, cardiova
1. Healthcare Services-This segment engages in the bio-pharma business. It offers DNA and RNA based tests for infectious diseases, oncology, endocrinology, transplantation typing, haematology, pharmacogenetics, and pre-natal and pre-implantation genetic diagnostics; and karyotype fluorescence in-situ hybridization analysis to detect targeted chromosome abnormalities.
1. Healthcare Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,840 Cr | 40.2 | 13.94% | ₹1,122 Cr | +26.1% |
| Suven Life Sciences Ltd. | ₹7,951 Cr | n/m | -78.80% | ₹1 Cr | +51.8% |
| Vimta Labs Ltd | ₹2,259 Cr | 29.5 | 18.55% | ₹112 Cr | -26.8% |
| Tarsons Products Limited | ₹1,730 Cr | 114.9 | 2.26% | ₹124 Cr | +25.7% |
| Brooks Laboratories Ltd. | ₹198 Cr | 7.9 | 22.28% | ₹19 Cr | -34.2% |
| Bilcare Ltd. | ₹194 Cr | 108.3 | -5.21% | — | — |
| Jeevan Scientific Technology Ltd | ₹176 Cr | 129.4 | 1.68% | — | +42.3% |
| Vivo Bio Tech Ltd. | ₹37 Cr | n/m | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹26 Cr | n/m | -68.79% | — | -45.3% |
Listed by market capitalisation. Ratios are shown for context only.
Dr. Habeebbullal Life Sciences Ltd is trading at ₹12.40, with a market capitalisation of ₹26 Cr.
Dr. Habeebbullal Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Dr. Habeebbullal Life Sciences Ltd has a return on equity of -68.79%.
Dr. Habeebbullal Life Sciences Ltd is listed on the BSE under the scrip code 539267.
Dr. Habeebbullal Life Sciences Ltd's share price is down 45.3% over one year and up 6.2% over three months. Its 52-week range is ₹10.15 to ₹24.55.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.